MBRX · Moleculin Biotech, Inc.
$0.61
+0.04 (+7.16%)
At close · Aug 14
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, the Company had an accumulated deficit of $226.5 million since inception and had not yet generated any revenues from operations. Additionally, management anticipates that its cash on hand of $7.3 million as of June 30, 2026, is not sufficient to fund its planned operations for a period of at least one year from when these condensed consolidated financial statements are issued. These factors raise substantial doubt regarding the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$11.92M
Shares
19.48M
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Past events
| Date | Event | Type |
|---|---|---|
| 2026-05-29 | Poster Presentation, 2026 American Society of Clinical Oncology (ASCO) Annual Meeting | Shareholder meeting |
| 2026-03-24 | 38th Annual ROTH Conference Fireside Chat | Conference |
| 2026-02-11 | Corporate Connect Webinar Series hosted by Webull Financial | Event |
| 2025-10-30 | The 14th Annual Acute Leukemia Meeting | Event |